Literature DB >> 1233229

Effect of rifampicin treatment on the metabolism of oestradiol and 17alpha-ethinyloestradiol by human liver microsomes.

H M Bolt, H Kappus, M Bolt.   

Abstract

Liver biopsies were obtained from four patients treated with rifampicin 600 mg for 6-10 days. Hepatic microsomes were incubated with an NADPH-regenerating system and the substrates [2,4,6,7-3H] oestradiol, [6,7-3H] oestradiol, [2,4,6,7-3H] ethinyloestradiol and [6,7-3H] ethinyloestradiol. The hydroxylation rates of these steroids at the labelled positions of rings A and B were determined by measuring the transformation of tritium into HTO by the microsomal enzymes. Comparison with previously published data showed that treatment with rifampicin caused a fourfold increase in the rate of hydroxylation of oestradiol and ethinyloestradiol at positions C-2/C-4 of ring A and C-6/C-7 of ring B. The acceleration of oestrogen hydroxylation by rifampicin was paralleled by an increase in microsomal cytochrome P-450, and also by microsomal reduction of rifampicin-quinone, a reactive metabolite of rifampicin. The increased aromatic hydroxylation of oestradiol and ethinyloestradiol leads to enhancement of their irreversible binding to microsomal protein. The data provide an explanation for the diminished efficacy of oestrogens in contraceptive formulations given to patients under treatment with rifampicin.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1233229     DOI: 10.1007/bf00562654

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  36 in total

1.  [Effects of rifampicin on the menstrual cycle and on oestrogen excretion in patients taking oral contraceptives].

Authors:  L Nocke-Finck; H Breuer; D Reimers
Journal:  Dtsch Med Wochenschr       Date:  1973-08-11       Impact factor: 0.628

2.  [The activity of N- and O-demethylase in the human liver].

Authors:  E Ackermann; I Heinrich
Journal:  Biochem Pharmacol       Date:  1970-02       Impact factor: 5.858

3.  Oxidative drug metabolism in human liver microsomes.

Authors:  E B Nelson; P P Raj; K J Belfi; B S Masters
Journal:  J Pharmacol Exp Ther       Date:  1971-09       Impact factor: 4.030

4.  Letter: Rifampicin and oral contraception.

Authors:  H M Bolt; H Kappus; M Bolt
Journal:  Lancet       Date:  1974-06-22       Impact factor: 79.321

5.  Pharmacokinetics of mestranol in man in relation to its oestrogenic activity.

Authors:  H M Bolt; W H Bolt
Journal:  Eur J Clin Pharmacol       Date:  1974-07-26       Impact factor: 2.953

6.  Metabolism of radioactive 17alpha-ethynylestradiol by women.

Authors:  M T Abdel-Aziz; K I Williams
Journal:  Steroids       Date:  1970-05       Impact factor: 2.668

7.  Mechanism of hepatic drug oxidation and its relationship to individual differences in rates of oxidation in man.

Authors:  D S Davies; S S Thorgeirsson
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

8.  Rifampicin: a new orally active rifamycin.

Authors:  N Maggi; C R Pasqualucci; R Ballotta; P Sensi
Journal:  Chemotherapy       Date:  1966       Impact factor: 2.544

9.  Pathway and stereochemistry of the formation of estriols in man.

Authors:  J Fishman; L Hellman; B Zumoff; J Cassouto
Journal:  Biochemistry       Date:  1966-06       Impact factor: 3.162

10.  Metabolism of 17alpha-ethynyl-(4-14C)oestradiol and (4-14C)mestranol in rat liver slices and interaction between 17alpha-ethynyl-2-hydroxyoestradiol and adrenalin.

Authors:  P Ball; H P Gelbke; O Haupt; R Knuppen
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1973-12
View more
  31 in total

1.  Effects of cytochrome P450 inducers on 17alpha-ethinyloestradiol (EE2) conjugation by primary human hepatocytes.

Authors:  A P Li; N R Hartman; C Lu; J M Collins; J M Strong
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria.

Authors:  F A Pieters; F Woonink; J Zuidema
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 3.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 4.  Inhibition and induction of cytochrome P450 and the clinical implications.

Authors:  J H Lin; A Y Lu
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

5.  Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.

Authors:  D Ouellet; A Hsu; J Qian; C S Locke; C J Eason; J H Cavanaugh; J M Leonard; G R Granneman
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

6.  Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects.

Authors:  E Perucca; R Grimaldi; G M Frigo; A Sardi; H Mönig; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 7.  Drug interactions that matter. A critical reappraisal.

Authors:  G T McInnes; M J Brodie
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 8.  Clinical implications of enzyme induction and enzyme inhibition.

Authors:  B K Park; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

9.  Effect of rifampicin treatment on the kinetics of mexiletine.

Authors:  P J Pentikäinen; I H Koivula; H A Hiltunen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man.

Authors:  S Wanwimolruk; W Kang; P F Coville; S Viriyayudhakorn; S Thitiarchakul
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.